OPB-111077 is under clinical development by Otsuka Pharmaceutical and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect OPB-111077’s likelihood of approval (LoA) and phase transition for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) took place on 02 Jun 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 02 Jun 2021 decreased OPB-111077’s Phase Transition Success Rate (PTSR) for Hematological Tumor.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their OPB-111077 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

OPB-111077 overview

OPB-111077 is under development for the treatment of hematological tumors including relapsed or refractory diffuse large B-cell lymphoma and refractory or newly diagnosed acute myeloid leukemia. The drug candidate is administered orally. OPB-111077 acts by targeting STAT3. It was also under development for solid tumors including hepatocellular carcinoma, refractory nasopharyngeal cancer.

Otsuka Pharmaceutical overview

Otsuka Pharmaceutical (OPC), a subsidiary of Otsuka Holdings Co Ltd, is a manufacturer and supplier of pharmaceuticals, food products, clinical testing, and medical equipment. The company develops formulations for diagnosis and treatment of central nervous system, oncology, cardiovascular and renal, gastrointestinal, ophthalmology disorders and infectious diseases through its pharmaceutical business. It’s nutraceutical segment offers rehydration, nutrition, vitamin supplements and cosmetics. OPC is investigating drugs for psychiatry and neurology; oncology; cardiovascular and other therapeutic indications in collaboration with academia and venture companies. The company operates branch offices, research facilities and factories in Japan. OPC is headquartered in Chiyoda-ku, Tokyo, Japan.

Quick View OPB-111077 LOA Data

Report Segments
  • Innovator
Drug Name
  • OPB-111077
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.